Heather Whittaker
Acute Care · Glen Burnie, MDNPI 1235821141
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 189 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 189 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$849
- Lilly USA, LLC$524
- AbbVie$253
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$242
- AstraZeneca$237
- Pfizer$222
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,682100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 41 | $849 |
| Lilly USA, LLC | 31 | $524 |
| AbbVie | 13 | $253 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $242 |
| AstraZeneca | 12 | $237 |
| Pfizer | 11 | $222 |
| Boehringer Ingelheim | 9 | $200 |
| Amgen(2 entities) | 7 | $137 |
| Dexcom, Inc. | 5 | $99 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $97 |
| Lundbeck LLC | 4 | $87 |
| GSK | 4 | $79 |
| Merck | 4 | $78 |
| Exact Sciences | 3 | $68 |
| Idorsia Pharmaceuticals US Inc | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 2 | $54 |
| Johnson & Johnson | 2 | $47 |
| Dynavax Technologies Corporation | 2 | $43 |
| Optinose US, Inc. | 2 | $39 |
| Corcept Therapeutics | 2 | $35 |
| Bayer | 2 | $33 |
| Medtronic | 2 | $32 |
| Axsome Therapeutics, Inc. | 2 | $30 |
| Seqirus USA Inc | 1 | $29 |
| Gilead | 1 | $25 |
| Astellas Pharma US Inc | 1 | $23 |
| Bausch Health US, LLC | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
How this compares
$3,682 in reported general payments places this provider in the 95th percentile of 502 acute care providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 64 | $75,490 |
| EliquisApixaban | 53 | $69,615 |
| OzempicSemaglutide | 22 | $35,633 |
| RybelsusSemaglutide | 20 | $32,340 |
| JanuviaSitagliptin Phosphate | 22 | $31,928 |
| FarxigaDapagliflozin Propanediol | 18 | $28,003 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $22,643 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 16 | $19,368 |
| MounjaroTirzepatide | 13 | $15,015 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $7,824 |
| Atorvastatin Calcium | 358 | $4,998 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $3,685 |
| Novolog FlexpenInsulin Aspart | 17 | $2,733 |
| Metoprolol Succinate | 136 | $2,590 |
| Pregabalin | 15 | $2,105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $200 | $75,49064 claims |
| PfizerEliquis | $222 | $69,61553 claims |
| Novo NordiskOzempic, Rybelsus | $849 | $67,97342 claims |
| MerckJanuvia, Janumet Xr | $78 | $51,29638 claims |
| AstraZenecaFarxiga | $237 | $28,00318 claims |
| Lilly USA, LLCMounjaro | $524 | $15,01513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 502 acute care providers in Maryland.
Other acute care in Glen Burnie
- Katrina Roux-BernsteinGlen Burnie$4K
- Paige GriffithBaltimore$106K
- Amanda ReaPerry Hall$65K
- T Nicole KelleyBaltimore$46K
- Amy GoodrichBaltimore$27K
- Rama AnthonyBaltimore$20K
- Susan HuppmannBaltimore$16K
- Eleanor DunlapBaltimore$11K
- Tierra AndersonTakoma Park$9K
- Lateaqua AlstonBaltimore$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.